TELA Bio Launches LIQUIFIX in the US

TELA Bio Inc., a commercial-stage medical technology company launched LIQUIFIX FIX8 Laparoscopic and LIQUIFIX Precision Open Hernia Mesh Fixation Devices in the US. Both devices are the only FDA-approved devices that affix mesh and approximate peritoneal tissue with liquid anchors. 
 
LIQUIFIX FIX8 is indicated for minimally invasive femoral and inguinal hernia repairs, and LIQUIFIX Precision is indicated for open femoral and inguinal hernia repairs. 
 
Removing the need for penetrating mechanical tacks, sutures, or staples, LIQUIFIX is a liquid adhesive for controlled mesh fixation. These products reduce the risk of mechanical tissue trauma since they do not breach patient tissue and allow surgeons to affix the mesh, minimalizing the risk of complications. 
 
LIQUIFIX products potentially offer greater utility for surgical mesh in inguinal hernia repair, enabling mesh fixation to sensitive areas, such as the “triangle of doom” and “triangle of pain.”  These regions contain sensitive arteries, veins, and nerves where traditional traumatic fixation methods could result in major vascular or nerve injuries leading to chronic pain.
 
“Aligned with our mission to prioritize the preservation and restoration of the patient’s own anatomy, this novel device is a natural addition to our fast-growing commercial portfolio,” TELA Bio President and CEO, Antony Koblish commented. “We’re excited to help surgeons across the U.S. advance the future of hernia repair fixation in robotic, laparoscopic, and open cases with this atraumatic approach.”
 
These products are manufactured in the UK by Advanced Medical Solutions Limited (AMS). AMS is a world-leading specialist in tissue healing technology and entered an agreement with TELA Bio in 2023. The agreement helped commercialize LIQUIFIX in the US.
 
“Based on my experience, the device is easy to use and is safe and effective,” said Mr. Paul Wilson, Consultant General Surgeon, who has used LIQUIFIX in over 1500 laparoscopic hernia repairs in the United Kingdom (U.K.). “The fixation strength is very impressive. I have seen a significant benefit to the patient, with a major reduction in both acute post-op pain and chronic pain after surgery. This has been a game-changer for me.”
 
“Given the consistent strong performance of the LIQUIFIX products in Europe and other international markets over the past three years, we look forward to working with TELA Bio to grow adoption in the U.S.,” said AMS CEO, Chris Meredith.